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Abstract
The occurrence and clinical impact of herpes simplex virus
(HSV) were evaluated in 342 bronchoalveolar lavage specimens
from 237 patients. HSV-1 and HSV-2 were detected in 32.1%
and <1% of patients, respectively. A significant difference of
HSV-1 prevalence and load was found in relation to admission
to intensive care unit, mechanical ventilation and mortality
within 28 days; in particular, a viral load ‡105 copies/mL bronc-
hoalveolar lavage fluid was significantly associated with critical
features. No association was found with immune status or other
characteristics. Nine of 21 (42.9%) cases of ventilator-associated
pneumonia were positive for HSV-1, with poor outcome in six.
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Herpes simplex virus (HSV) is a dsDNA virus encompassing
two highly seroprevalent subtypes, HSV-1 and HSV-2 [1]. In
critically ill patients, HSV-1 has been reported in 22–54% and
16–32% in the upper and lower respiratory tract, respectively
[2–6], and it is increasingly associated with pulmonary diseases
with poor outcome, particularly in the presence of load >105
copies/mL bronchoalveolar lavage fluid [5–12]. HSV-1 has
been proposed as a severity marker in ventilator-associated
pneumonia [11]. However, it is unknown whether HSV is a
true lung pathogen or whether its detection represents
asymptomatic local reactivation in the presence of other
pathogens. Herein, we prospectively evaluated the occurrence
and significance of HSV in 342 consecutive bronchoalveolar
lavage specimens from 237 patients (male/female, 149/88;
mean age, 56.4 years) over a 12-month period. Specimens
from the same patient that were collected <2 weeks apart
and those from patients admitted to the hospital <48 h before
bronchoalveolar lavage sampling were excluded. Indications
for bronchoalveolar lavage (performed as previously described
[13]) included respiratory symptoms, new infiltrates on chest
X-ray or routine follow-up in lung transplant recipients (at
month 1 post-transplantation and subsequently at 3-month
intervals). The following features were collected: immune
(defined as previously reported [13]) and transplant statuses,
comorbidities, co-infections (evaluated using a diagnostic panel
including bacterial, fungal and other viral agents [14]), admit-
tance and length of stay in intensive-care unit (ICU), total
length of hospital stay, mechanical ventilation, ventilator-asso-
ciated pneumonia (diagnosed according to CDC definitions
[15]), mortality within 28 days. The occurrence of HSV-1 and
HSV-2 was evaluated by real-time PCR (R-geneTM, Argene
Inc., Verniolle, France) targeting the US7 and US2 genes,
respectively. According to our centre’s practice, HSV diagnos-
tics also included rapid shell vial isolation on Vero cell cultures
[13]. For statistical analysis, chi-square test and t test were
used. A p value <0.05 was considered significant.
Overall, HSV-1-DNA was detected in 86/342 (25.1%) spec-
imens from 76/237 (32.1%) patients and HSV-2 was detected
in three (0.9%) from as many patients. HSV infection was con-
firmed by viral isolation in 85% of specimens, with discordant
results occurring mostly in cases receiving acyclovir. HSV-1
occurrence and load in relation to clinical features are
reported in Table 1. A significant difference of prevalence and
load was found in relation to admission to ICU, mechanical
ventilation and mortality within 28 days; as well as occur-
rence of co-infections, evaluated in single specimens, with
other herpesviruses (mainly cytomegalovirus, including 18
cases of histopathologically confirmed cytomegalovirus pneu-
monia) and bacterial agents being the most commonly
detected. No significant difference was found as regards
immune and transplant status, and presence of comorbidities.
Also, length of stay in ICU and total length of stay in hospital
were not significantly different between HSV-1-positive
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(means: 28 and 43 days, respectively) and HSV-1-negative (19
and 32, respectively) patients. In the subgroup of follow-up
specimens from lung transplant recipients, in comparison to
those collected for symptomatic indications, HSV-1 occur-
rence and load were not significantly different. In patients
with ventilator-associated pneumonia, 9/21 (42.9%) cases
were positive for HSV-1 (mean viral load, 1.8 · 106 copies/
mL) and six of these patients (66.7%) died within 3–120 days
(main agents: Staphylococcus aureus, Pseudomonas aeruginosa,
Streptococcus pneumoniae, Escherichia coli, gram-negative bacte-
ria). Five of these patients received acyclovir. As regards the
impact of high-level viral replication, the prevalence of admis-
sion to ICU, mechanical ventilation and death within 28 days
was significantly higher in the presence of an HSV-1 load
‡105 copies/mL; whereas no significant difference was found
in relation to the immune status (Fig. 1). Multiple specimens
were available for 46 patients (range, two to seven speci-
mens), 19 of whom were positive in at least one specimen
and 11 of whom were positive in consecutive samples.
Among patients with consecutively positive specimens, five
were asymptomatic lung transplant recipients with viral loads
<103 copies/mL and usually persisting at the subsequent eval-
uation at 3 months; six were from ICU and showed a typical
pattern of HSV-1 kinetics with positivity appearing within
1 week of mechanical ventilation and an exponential increase
in viral load (about 5 logs) in subsequent specimens, as
reported in other studies [10]. The treatment was started at
the clinician’s discretion and no significant difference in out-
come or decay in viral load was found between acyclovir-
treated patients (n = 29; including 18 ICU patients, eight
transplant recipients and two others) and not treated
patients. Interestingly, HSV-1 was positive in bronchoalveolar
lavage specimens (by both molecular methods and viral isola-
tion), in six of ten ICU patients with influenza AH1N1v (mean
HSV-1 load, 7.2 · 105). All these patients received oseltamivir
and three received acyclovir. Five of these patients died
within 2 weeks of bronchoalveolar lavage and three of them
(60%) were also HSV-1-positive in lung samples taken at
autopsy by both molecular methods and rapid viral isolation.
Overall, HSV-1 was detected frequently, with rates similar
to those previously reported (up to 35%) [5,6,10]. No signifi-
cant difference of prevalence according to immune and trans-
plant status, as well as comorbidities, was found; whereas
HSV-1 prevalence and load were significantly higher in the
presence of critical features such as admission to ICU,
mechanical ventilation and mortality within 28 days. The eval-
uation of the subgroup of surveillance specimens in lung
transplant recipients, which may be considered as controls
with immunosuppression but no traumatic or inflammatory
stimulus, showed no significant difference in comparison to
specimens collected from symptomatic patients, although the
TABLE 1. Results of herpes simplex type 1 (HSV-1) DNA
detection in bronchoalveolar lavage specimens and associa-
tion with clinical features of study population
Feature
(total number)
HSV-1-
positive
n (%) p
HSV-1
Mean viral
load
(copies/mL
BAL) p
Patients (n = 237) 73 (30.8%) – 5.7 · 105 –
Specimens (n = 342) 86 (25.1%) 5.6 · 105
Age
£50 years (n = 76) 23 (30.2%) 0.98 4.4 · 105 0.49
>50 years (n = 161) 50 (31.1%) 5.8 · 105
Indication to BALa
Symptomatic (n = 331) 83 (25.1%) 0.85 5.8 · 105 0.49
Surveillance (n = 11) 3 (27.3%) 6 · 103
Admission to ICU
Yes (n = 99) 37 (37.4%) 0.007 1.03 · 106 0.002
No (n = 138) 36 (26.1%) 8.8 · 104
Immune status
Competent
(n = 123)
38 (30.9%) 0.91 2.6 · 105 0.89
Compromised
(n = 114)
35 (30.7%) 1.9 · 105
Transplant status
Yes (n = 78) 24 (30.8%) 0.88 4.6 · 105 0.62
No (n = 159) 49 (30.8%) 6.2 · 105
Comorbidities
Yes (n = 73) 23 (31.5%) 0.90 8.4 · 105 0.13
No (n = 164) 52 (31.7%) 3.5 · 105
Mechanical ventilation
Yes (n = 72) 30 (41.6%) 0.04 1.2 · 106 0.0008
No 165 45 (27.3%) 1.4 · 105
Coinfectionsa
Yes 203 64 (31.5%) 0.002 7.3 · 105 0.07
No 139 22 (15.8%) 8.4 · 104
Death within 28 days
Yes 39 20 (51.3%) 0.004 1.2 · 106 0.018
No 198 53 (26.7%) 3.3 · 105
For evaluation of mean viral load, peak values in each patient were considered.
BAL, bronchoalveolar lavage; ICU, intensive-care unit; n, number; ns, not signifi-
cant.
aAs regards indication to BAL (see text for details) and presence of co-infec-
tions, single episodes and not patients were evaluated.
The chi-square test was used for comparisons of prevalence between groups
(third column); the Student’s t test was used for comparison of mean viral load
values (fifth column).
p < 0.0001 
p = 0.016 
p = 0.6 
p = 0.013 
FIG. 1. Prevalence of admission to intensive care unit (ICU),
mechanical ventilation, immunosuppression and death within 28 days
according to viral load of herpes simplex virus type 1 in bronchoal-
veolar lavage specimens: ‡105 (dark bars) versus <105 copies/mL
(white bars).
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low number of specimens should be considered. Interest-
ingly, HSV-1 infection was frequent in the presence of venti-
lator-associated pneumonia, with a higher prevalence rate
than that previously reported [11]. However, given the smal-
ler number of patients in our series, further studies should
be performed, particularly in consideration of the poor out-
come. As previously suggested [6], a viral load ‡105 copies/
mL was associated with severity features, in contrast to the
lack of association with immunocompromised conditions.
The relevance of these findings should also be more appro-
priately evaluated considering the occurrence of co-infec-
tions. It has been suggested that the mucosal damage
associated with intubation and mechanical ventilation is a
potential trigger for HSV-1 reactivation and that aspiration
from the upper respiratory tract represents the main source
of lower respiratory tract infections. Nevertheless, no con-
clusion can be drawn as to the causative role in lung and fur-
ther studies on tissue specimens and randomized medical
intervention analyses are needed [16].
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